Table 4 Multivariate logistic regression analysis of the likelihood of achieving optimum viral load suppression within four and eight weeks among noncirrhotic patients. (N = 350).
Achieve optimum viral load suppression within four weeks | Achieve optimum viral load suppression within eight weeks | |||||
|---|---|---|---|---|---|---|
OR | 95% CI | p valuea | OR | 95% CI | p valuea | |
Sex | ||||||
Female (ref) | 1.000 | – | – | 1.000 | – | – |
Male | 0.563 | 0.300–1.058 | 0.074 | 0.906 | 0.278–2.955 | 0.870 |
Age group (years) | ||||||
< 45 (ref) | 1.000 | – | – | 1.000 | – | – |
≥ 45 | 0.812 | 0.517–1.273 | 0.364 | 2.152 | 0.906–5.109 | 0.082 |
HCV genotype | ||||||
6 (ref) | 1.000 | – | – | 1.000 | – | – |
1 | 1.067 | 0.540–2.107 | 0.852 | 1.420 | 0.452–4.467 | 0.548 |
2 | 4.792 | 0.371–61.97 | 0.230 | 19E07 | 0 | 0.999 |
3 | 1.290 | 0.636–2.613 | 0.480 | 2.637 | 0.734–9.478 | 0.137 |
IL-28B genotype | ||||||
CT + TT (ref) | 1.000 | – | – | 1.000 | – | – |
CC | 0.933 | 0.543–1.603 | 0.802 | 1.439 | 0.557–3.721 | 0.453 |
HIV coinfection | ||||||
No (ref) | 1.000 | – | – | 1.000 | – | – |
Yes | 1.357 | 0.819–2.249 | 0.236 | 1.636 | 0.644–4.160 | 0.301 |
Previous interferon treatment exposure | ||||||
Treatment-experienced (ref) | 1.000 | – | – | 1.000 | – | – |
Treatment-naïve | 1.909 | 1.032–3.529 | 0.039 | 0.902 | 0.296–2.748 | 0.856 |
Injection drug use | ||||||
No | 1.000 | – | – | 1.000 | – | – |
Yes | 1.721 | 1.024–2.893 | 0.040 | 1.009 | 0.400–2.546 | 0.985 |
Use of concomitant medications | ||||||
No | 1.000 | – | – | 1.000 | – | – |
Yes | 0.657 | 0.314–1.374 | 0.264 | 0.436 | 0.088–2.153 | 0.308 |
Comorbidities | ||||||
No | 1.000 | – | – | 1.000 | – | – |
Yes | 0.819 | 0.421–1.596 | 0.558 | 0.802 | 0.248–2.597 | 0.713 |
